Ajanta Pharma Ltd.
Snapshot View

View in App

Prices View details >>

1208.55 +3.35 ▲0.3%

31 March 2023, 04:01:00 PM
Volume: 854

Overview View Details >>

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.ajantapharma.com
Market Cap 15,489.69 Cr.
Enterprise Value(EV) 15,157.61 Cr. 2022-09
Financial Indicators
Earnings per share (EPS) 48.15 Trailing Twelve Months Ending 2022-12
Price-Earning Ratio (PE) 25.10 Trailing Twelve Months Ending 2022-12
Industry PE 32.41 Trailing Twelve Months Ending 2022-12
Book Value / Share 291.76 Trailing Twelve Months Ending 2022-12
Price to Book Value 4.14 Calculated using Price: 1,208.55
Dividend Yield 0.52 Period Ending 2022-03
No. of Shares Subscribed 12.81 Cr. 128,125,155 Shares
FaceValue 2
Company Profile
Ajanta Pharma is a specialty pharmaceutical company engaged in development, manufacturing and marketing of quality finished dosages. Its business includes Branded Generics in emerging markets of Asia and Africa, Generics in the developed markets of USA and Institution sales. Emerging markets are the major contributors in company's branded generic business where it is present across Asia and Africa. It has designed customised basket of products for each of these markets and serve wide range of therapeutic segments like Anti-Biotic, Anti-Malarial, Anti-Diabetic, Cardiology, Gynecology, Orthopedics, Pediatric, Respiratory & General Health products.

Delivery View Details >>

Delivered Qty
Traded Qty

Performance View Details >>

1 Day
+0.28%
1 Week
+2.24%
1 Month
+2.57%
3 Month
-0.17%
6 Month
-4.05%
1 Year
+0.20%
2 Year
+1.09%
5 Year
+28.95%
10 Year
+956.61%

Ratios View Details >>

9 years 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03
Return on Equity (%) 47.47 43.24 40.93 36.77 26.00 18.07 19.32 23.38 22.77
Return on Capital Employed (%) 54.52 56.43 51.59 45.72 34.49 23.84 27.44 32.20 29.37
Return on Assets (%) 28.05 29.57 31.66 30.69 22.06 14.52 14.44 17.03 16.79

Balance Sheet View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-09* Rs. Cr.
Shh. Funds 593 841 1,191 1,568 2,041 2,245 2,599 2,996 3,264 3,603
Non Curr. Liab. 81 56 29 9 39 162 228 275 279 65
Curr. Liab. 275 250 260 247 346 498 746 839 838 705
Minority Int.
Equity & Liab. 949 1,146 1,479 1,823 2,426 2,906 3,572 4,109 4,381 4,373
Non Curr. Assets 429 513 716 973 1,202 1,605 1,791 1,891 1,926 1,725
Curr. Assets 520 633 763 851 1,224 1,301 1,781 2,218 2,455 2,649
Misc. Exp. not W/O
Total Assets 949 1,146 1,479 1,823 2,426 2,906 3,572 4,109 4,381 4,373

Profit Loss View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-12 Rs. Cr. TTM
Net Sales 1,208 1,474 1,734 1,983 2,126 2,055 2,588 2,890 3,341 3,731
Other Income 14 17 21 24 24 21 92 26 116 138
Total Income 1,222 1,490 1,755 2,007 2,150 2,076 2,680 2,916 3,457 3,869
Total Expenditure -840 -968 -1,147 -1,296 -1,467 -1,489 -1,905 -1,891 -2,412 -2,937
PBIDT 382 522 608 711 683 588 776 1,025 1,045 932
Interest -9 -6 -5 -1 0 -1 -12 -8 -10 -12
Depreciation -44 -52 -44 -61 -60 -72 -96 -116 -125 -129
Taxation -96 -146 -143 -141 -154 -127 -196 -246 -197 -174
Exceptional Items -8 -4
PAT 234 310 416 507 469 387 468 654 713 617
Minority Interest
Share Associate
Other Related Items
Consolidated Net Profit 234 310 416 507 469 387 468 654 713 617
Adjusted EPS 18 23 31 38 36 30 36 50 56 48

Cash Flow View Details >>

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Cash Fr. Operatn. 234 212 279 326 609 281 375 457 576 562
Cash Fr. Inv. -104 -188 -158 -209 -383 -256 -223 -224 -282 -74
Cash Fr. Finan. -104 -20 -105 -117 -202 0 -147 -129 -318 -460
Net Change 26 4 16 0 24 25 4 104 -24 28
Cash & Cash Eqvt 34 39 54 41 66 91 95 199 178 205

Shareholding Pattern View Details >>

9 Qtrs 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%)
Promoter 70.34 70.34 70.34 70.34 70.34 70.48 70.48 70.48 66.11
Public 29.66 29.66 29.66 29.66 29.66 29.52 29.52 29.52 33.89
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 15.17 15.49 14.95 13.73 15.37 16.60 20.09 17.42 19.87

Announcements View Details >>

Fri, 31 Mar 2023
Closure of Trading Window
Pursuant to provisions of SEBI (Prohibition of Insider Trading) Regulations 2015 as amended from time to time and Ajantas Code of Conduct for Insiders the Trading Window for dealing in securities of the Company shall remain closed for Designated Persons (as defined in the Code) from close of business hours of Friday 31st March 2023 till 48 hours after the declaration of Financial Results of the Company for the quarter and year ended 31st March 2023.
Tue, 28 Mar 2023
Submission Of Letter Of Offer
With reference to the captioned Buyback and in furtherance of our earlier intimation regarding submission of Public Announcement dated March 13 2023 published on March 14 2023 please find enclosed the Letter of Offer dated March 28 2023 along with the Tender Forms for demat and physical shareholders which are being dispatched by the Company to the Eligible Shareholders within two working days from the Record Date being March 24 2023.
Tue, 14 Mar 2023
Announcement under Regulation 30 (LODR)-Public Announcement-Buyback of Shares
This is in furtherance to our intimation dated March 10 2023 informing the stock exchanges w.r.t. Buy-back of 22 10 500 shares of the Company at a price of ? 1 425/- per equity share on a proportionate basis through the tender offer process (Buyback) in accordance with the provisions of the Companies Act 2013 and rules made thereunder and theSecurities and Exchange Board of India (Buy-Back of Securities) Regulations 2018 (the SEBI Buyback Regulations) as amended from time to time and other applicable laws.In this regard please find enclosed:(a) A copy of the Public Announcement as published in newspapers; and(b) Certified true copy of the resolution passed by the Board of Directors on dated March 10 2023 for approving the proposal of Buyback.You are requested to kindly take the same on record.

Technical Scans View Details >>

Fri, 31 Mar 2023
Close Within 52 Week Low Zone Close Within 52 Week Low Zone
Closing Near 100 SMA Closing Near 100 SMA
Close Crossing 100 SMA From Below Close Crossing 100 SMA From Below
Closing Near 20 SMA Closing Near 20 SMA
CCI Trending Up CCI Trending Up

Related Stocks View Details >>

  • SALES
Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 235,878.62 983.10 -0.8%
Dr. Reddy's Laboratories Ltd. 76,960.86 4,624.15 +1.3%
Divi's Laboratories Ltd. 75,014.78 2,826.00 +0.3%
Cipla Ltd. 72,696.02 900.65 +1.4%
Apollo Hospitals Enterprise Ltd. 61,962.56 4,309.40 -1.3%
Torrent Pharmaceuticals Ltd. 52,030.91 1,543.40 +0.2%
Zydus Lifesciences Ltd. 49,749.83 491.00 +0.1%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-12 56.00 983.10 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 21.13 4,624.15 +1.3%
Divi's Laboratories Ltd. Consolidated 2022-12 31.30 2,826.00 +0.3%
Cipla Ltd. Consolidated 2022-12 27.55 900.65 +1.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-12 81.03 4,309.40 -1.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 62.86 1,543.40 +0.2%
Zydus Lifesciences Ltd. Consolidated 2022-12 24.11 491.00 +0.1%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-12 4.26 983.10 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 3.50 4,624.15 +1.3%
Divi's Laboratories Ltd. Consolidated 2022-12 6.03 2,826.00 +0.3%
Cipla Ltd. Consolidated 2022-12 3.20 900.65 +1.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-12 10.04 4,309.40 -1.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 8.19 1,543.40 +0.2%
Zydus Lifesciences Ltd. Consolidated 2022-12 2.88 491.00 +0.1%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 0.03 983.10 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 0.18 4,624.15 +1.3%
Divi's Laboratories Ltd. Consolidated 2022-03 0.00 2,826.00 +0.3%
Cipla Ltd. Consolidated 2022-03 0.04 900.65 +1.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 0.47 4,309.40 -1.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 0.68 1,543.40 +0.2%
Zydus Lifesciences Ltd. Consolidated 2022-03 0.25 491.00 +0.1%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 983.10 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.93 4,624.15 +1.3%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 2,826.00 +0.3%
Cipla Ltd. Consolidated 2022-03 13.10 900.65 +1.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,309.40 -1.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,543.40 +0.2%
Zydus Lifesciences Ltd. Consolidated 2022-03 15.51 491.00 +0.1%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 983.10 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.93 4,624.15 +1.3%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 2,826.00 +0.3%
Cipla Ltd. Consolidated 2022-03 13.10 900.65 +1.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,309.40 -1.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,543.40 +0.2%
Zydus Lifesciences Ltd. Consolidated 2022-03 15.51 491.00 +0.1%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 38,654.49 983.10 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 21,545.20 4,624.15 +1.3%
Divi's Laboratories Ltd. Consolidated 2022-03 8,959.83 2,826.00 +0.3%
Cipla Ltd. Consolidated 2022-03 21,763.34 900.65 +1.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 14,662.60 4,309.40 -1.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8,508.04 1,543.40 +0.2%
Zydus Lifesciences Ltd. Consolidated 2022-03 15,265.20 491.00 +0.1%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 3,405.82 983.10 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 2,182.50 4,624.15 +1.3%
Divi's Laboratories Ltd. Consolidated 2022-03 2,960.45 2,826.00 +0.3%
Cipla Ltd. Consolidated 2022-03 2,559.47 900.65 +1.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 1,101.10 4,309.40 -1.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 777.18 1,543.40 +0.2%
Zydus Lifesciences Ltd. Consolidated 2022-03 2,326.40 491.00 +0.1%

FAQ's On Ajanta Pharma Ltd.

What is Ajanta Pharma share price?
Can I buy Ajanta Pharma shares now?
What is the Dividend Yield of Ajanta Pharma?
What is the Market Cap of Ajanta Pharma?
What are the key metrics to analyse Ajanta Pharma?
What is the 52 Week High and Low of Ajanta Pharma?
What is the trend of Ajanta Pharma share price?